Adjuvant and neoadjuvant therapy for renal cell carcinoma: A survey of the Society of Urologic Oncology

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1316-1320

  Tobert, Conrad M ^a,b   Uzzo, Robert G ^c   Wood, Christopher G ^d   Lane, Brian R ^a,b  

^a SPECTRUM HEALTH   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Kidney neoplasms; Nephrectomy; Targeted molecular therapy

Indexed keywords

AXITINIB; DENDRITIC CELL VACCINE; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER SURGERY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; NEPHRECTOMY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED STATES;

KIDNEY NEOPLASMS; NEPHRECTOMY; TARGETED MOLECULAR THERAPY;

CANADA; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; NEPHRECTOMY; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; SOCIETIES, MEDICAL; UNITED STATES; UROLOGY;

EID: 84884675243     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.12.014     Document Type: Article

References (28)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Rini B.I. Metastatic renal cell carcinoma: Many treatment options, one patient. J Clin Oncol 2009, 27:3225-3234.
3. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
4. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
5. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
6. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
7. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon-α, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
8. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
9. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
10. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009, 373:1119-1132.
11. Rini B.I. New strategies in kidney cancer: Therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 2010, 16:1348-1354.
12. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon-α-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
13. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon-α alone in metastatic renal-cell carcinoma: A randomized trial. Lancet 2001, 358:966-970.
14. Flanigan R.C., Mickisch G., Sylvester R., et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol 2004, 171:1071-1076.
15. Smaldone M.C., Fung C., Uzzo R.G., et al. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. Hematol Oncol Clin North Am 2011, 25:765-791.
16. Margulis V., Matin S.F., Tannir N., et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008, 180:94-98.
17. Thomas A.A., Rini B.I., Stephenson A.J., et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009, 182:881-886.
18. Wood C.G., Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: A new treatment paradigm for locally advanced and metastatic disease. Cancer 2009, 115:2355-2360.
19. Hellenthal N.J., Underwood W., Penetrante R., et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010, 184:859-864.
20. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
21. Figlin RA, Amin A, Dudek AZ, et al. Encouraging progression-free survival results in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) participating in a phase II study testing the safety and activity of a dendritic cell-based immunotherapeutic (AGS-003) in combination with sunitinib. Chicago, Proceedings of the KCA October 2010; [Abstract].
22. Abel E.J., Culp S.H., Tannir N.M., et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011, 59:10-15.
23. Bex A., Jonasch E., Kirkali Z., et al. Integrating surgery with targeted therapies for renal cell carcinoma: Current evidence and ongoing trials. Eur Urol 2010, 58:819-828.
24. Thomas A.A., Rini B.I., Lane B.R., et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009, 181:518-523. Discussion 523.
25. Amin C., Wallen E., Pruthi R.S., et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008, 72:864-868.
26. Cowey C.L., Amin C., Pruthi R.S., et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010, 28:1502-1507.
27. Abel E.J., Culp S.H., Matin S.F., et al. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: Comparison with nephrectomy assessment. J Urol 2010, 184:1877-1881.
28. Powles T., Kayani I., Blank C., et al. : The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol 2011, 22:1041-1047.